Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients whose conditions are defined as definite ALSor probable ALSdiagnostic criteria El Escorial and revised Airlie House.~* Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life.~* Patients of less than 2 years after the onset of ALS.~* Patients whose progress of the condition during 12 weeks before administration meet other requirements.~Exclusion Criteria:~* Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.~* Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.~* Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present.~* In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).